RNA interference (RNAi) targeted gene therapy has been employed in novel cancer treatments (ex HER2+) (Gavrilov and Saltzman, 2012; Mansoori et al., 2014; Ahmed et al., 2015). Here, ERBB2 is linked to cancer.